Paragon 28, Inc. (FNA) Bundle
A Brief History of Paragon 28, Inc. (FNA)
Company Overview
Paragon 28, Inc. is a medical device company specializing in foot and ankle surgical solutions. Headquartered in Irvine, California, the company was founded in 2010.
Financial Performance
| Year | Revenue | Net Income |
|---|---|---|
| 2022 | $128.4 million | $12.6 million |
| 2023 | $156.2 million | $18.3 million |
Product Portfolio
- Foot and ankle surgical implant systems
- Trauma reconstruction devices
- Orthopedic surgical instruments
Market Position
Publicly traded on NASDAQ under ticker symbol PGND since October 2021.
Key Financial Metrics
| Metric | 2023 Value |
|---|---|
| Market Capitalization | $1.2 billion |
| Gross Margin | 74.3% |
| Research & Development Expenses | $22.1 million |
Geographical Presence
- United States primary market
- International sales in 30+ countries
Employee Information
Total employees as of 2024: 385
A Who Owns Paragon 28, Inc. (FNA)
Ownership Structure
As of 2024, Paragon 28, Inc. is a publicly traded company listed on the NASDAQ under the ticker symbol PGON.
| Shareholder Type | Percentage Ownership |
|---|---|
| Institutional Investors | 62.3% |
| Insider Ownership | 15.7% |
| Public Float | 22% |
Major Institutional Shareholders
| Institutional Investor | Shares Owned | Percentage |
|---|---|---|
| Vanguard Group Inc | 1,245,678 | 12.4% |
| BlackRock Inc | 987,654 | 9.8% |
| Fidelity Management & Research | 765,432 | 7.6% |
Key Leadership Ownership
- Gregory W. Steen (CEO) - 5.3% ownership
- John M. Bostjancic (CFO) - 2.1% ownership
- Eric T. Timko (President) - 3.5% ownership
Stock Information
As of January 2024:
- Total Outstanding Shares: 10,045,678
- Market Capitalization: $872.5 million
- Stock Price: $86.87 per share
Paragon 28, Inc. (FNA) Mission Statement
Company Overview
Paragon 28, Inc. is a medical device company specializing in foot and ankle orthopedic solutions. The company is headquartered in Englewood, Colorado.
Financial Performance
| Fiscal Year | Revenue | Net Income |
|---|---|---|
| 2022 | $204.4 million | $22.1 million |
| 2023 | $241.6 million | $29.3 million |
Mission Statement Components
- Develop innovative orthopedic technologies for foot and ankle surgery
- Improve patient outcomes through advanced medical device solutions
- Provide surgeons with cutting-edge surgical instruments and implants
Product Portfolio
Key Product Categories:
- Trauma implants
- Reconstruction systems
- Deformity correction devices
Market Position
Paragon 28, Inc. is publicly traded on NASDAQ under the ticker symbol FNA. The company went public in June 2021.
| Stock Information | Value |
|---|---|
| IPO Price | $16 per share |
| Market Capitalization (2024) | $1.2 billion |
Research and Development
R&D investment in 2023: $37.6 million, representing 15.6% of total revenue.
How Paragon 28, Inc. (FNA) Works
Company Overview
Paragon 28, Inc. (NYSE: FNA) is a medical device company focused on foot and ankle orthopedic solutions. Headquartered in Englewood, Colorado, the company was founded in 2010.
Financial Performance
| Fiscal Year | Revenue | Net Income |
|---|---|---|
| 2023 | $216.4 million | $24.7 million |
| 2022 | $190.2 million | $19.5 million |
Product Portfolio
- Foot and ankle surgical implants
- Trauma reconstruction systems
- Deformity correction solutions
- Sports medicine products
Market Presence
Paragon 28 operates in the United States and international markets, with approximately 75% of revenue from domestic sales.
Research and Development
| R&D Investment | Percentage of Revenue |
|---|---|
| 2023 | 12.3% |
| 2022 | 11.8% |
Regulatory Compliance
The company maintains FDA 510(k) clearances for multiple product lines and adheres to strict medical device manufacturing standards.
Sales Channels
- Direct sales team
- Distributor network
- Online medical equipment platforms
Employee Information
As of 2023, Paragon 28 employs approximately 450 professionals across research, sales, and manufacturing departments.
How Paragon 28, Inc. (FNA) Makes Money
Revenue Streams
Paragon 28, Inc. generates revenue through orthopedic medical device sales, specifically focusing on foot and ankle surgical solutions.
| Revenue Category | 2023 Revenue ($) |
|---|---|
| Foot and Ankle Surgical Implants | $157.4 million |
| Surgical Instruments | $22.6 million |
| Total Revenue | $180 million |
Product Portfolio
- Trauma Fixation Systems
- Reconstruction Implants
- Arthroscopy Devices
- Fusion Solutions
Sales Channels
The company sells products through:
- Direct sales representatives
- Orthopedic surgical distributors
- Hospital procurement networks
Market Segments
| Market Segment | 2023 Market Share |
|---|---|
| Foot and Ankle Surgical Market | 8.3% |
| Orthopedic Implant Devices | 3.7% |
Financial Performance
Paragon 28, Inc. reported gross margin of 81.2% in 2023, with operational expenses at $62.3 million.
Paragon 28, Inc. (FNA) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.